相似文献
1
Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience.
Transplant Proc. 1998 Jun;30(4):1391-3. doi: 10.1016/s0041-1345(98)00285-1.
2
Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.
Transplant Proc. 2001 May;33(3):2330-1. doi: 10.1016/s0041-1345(01)02011-5.
3
One hundred children treated with tacrolimus after primary orthotopic liver transplantation.
Transplant Proc. 1998 Jun;30(4):1397-8. doi: 10.1016/s0041-1345(98)00287-5.
4
Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation.
Transplant Proc. 2001 May;33(3):2258-62. doi: 10.1016/s0041-1345(01)01983-2.
5
Impact of immunosuppression in liver transplantation across a positive crossmatch.
Transplant Proc. 1998 Jun;30(4):1466-7. doi: 10.1016/s0041-1345(98)00318-2.
6
Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation.
Transplant Proc. 1998 Dec;30(8):3946-7. doi: 10.1016/s0041-1345(98)01298-6.
7
Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience.
Transplant Proc. 2000 Nov;32(7):1733-5. doi: 10.1016/s0041-1345(00)01396-8.
8
Does initial graft function influence the outcome after liver transplantation?
Transplant Proc. 1998 Jun;30(4):1464-5. doi: 10.1016/s0041-1345(98)00317-0.
9
Experience with neoral cyclosporine through the oral route in liver transplantation.
Transplant Proc. 1998 Jun;30(4):1432-4. doi: 10.1016/s0041-1345(98)00303-0.
10
Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
Transplant Proc. 1998 Jun;30(4):1443-4. doi: 10.1016/s0041-1345(98)00308-x.
Zotero 插件